For example, one study demonstrated how engineered EVPs, containing therapeutic siRNA, could target glioma cells by expressing a protein that binds to neuropilin-1 (NRP-1), which is recognized for its overexpression on the surface of these cells (Jia et al., 2018). Here, NRP1 is linked to central nervous system cancer.